Azitra, Inc.

Precision dermatology powered by microbial and genetic engineering
Developing novel therapeutics to treat adverse skin conditions and disease

[Azitra, Inc. @azitrainc]

Learn about ATR04 - a live biotherapeutic product candidate including an isolated, naturally derived Staphylococcus epidermidis strain in development for EGFRI-associated skin rash.
https://t.co/nAIkeunABh

[Azitra, Inc. @azitrainc]

About Cancer Therapy-Associated Rash: Targeted cancer therapies have produced significant treatment advances for patients w/ a variety of tumors including non-small cell lung cancer (NSCLC) and colorectal cancer, but they are also associated with unique dermatologic toxicities.

[Azitra, Inc. @azitrainc]

These side effects can severely hamper treatment efforts. The papulopustular rash is often the earliest & most common dermatologic adverse event of EGFRi treatment and can occur in 50-80% of patients, often impacting quality of life severely enough to interrupt or stop treatment.

[Azitra, Inc. @azitrainc]

More on @azitrainc's work to utilize topical filaggrin + bacterial lysate for cosmeceutical indications & a potential mechanism of action for addressing the appearance of fine lines and wrinkles #Biotech #PrecisionDerm #Cosmetics #Cosmeceutical $AZTR

[Azitra, Inc. @azitrainc]

@azitrainc recently launched innovative protein and peptide programs for the #cosmetic & #cosmeceutical markets leveraging proprietary filaggrin technologies.

Learn more here: https://t.co/9Tedtd17oh

$AZTR #biotech

[Azitra, Inc. @azitrainc]

@azitrainc pipeline key facts
-ATR-12: LEKTI-Secreting Staphylococcus epidermidis for Netherton syndrome
-ATR-04: auxotrophic S. epidermidis for EGFR inhibitor-associated rash
-ATR-01: topical filaggrin protein for ichthyosis vulgaris
Learn more here: https://t.co/knzrzvg511

[Azitra, Inc. @azitrainc]

From our CEO in today's release: @azitrainc Announces New U.S. Patent Protecting ATR-12 Program #NethertonSyndrome #RareDisease #PrecisionDerm #Dermatology #PrecisionMedicine

[Azitra, Inc. @azitrainc]

@azitrainc Announces New U.S. Patent Protecting ATR-12 Program

#NethertonSyndrome #RareDisease #PrecisionDerm #Dermatology #PrecisionMedicine

https://t.co/KG75v9PBX1

[Azitra, Inc. @azitrainc]

@azitrainc Announces New U.S. Patent Protecting ATR-12 Program

#NethertonSyndrome #RareDisease #PrecisionDerm #Dermatology #PrecisionMedicine

https://t.co/KG75v9PBX1

[Azitra, Inc. @azitrainc]

More from this week's announcement. See the release here - https://t.co/D2aGjq0Yfv

#IchthyosisVulgaris #PrecisionDerm #Dermatology #PrecisionMedicine

[Azitra, Inc. @azitrainc]

@azitrainc Announces Poster Presentation at ASGCT 2026 Highlighting ATR-01 Program for Ichthyosis Vulgaris
#IchthyosisVulgaris #PrecisionDerm #Dermatology #PrecisionMedicine
https://t.co/D2aGjq0Yfv

[Azitra, Inc. @azitrainc]

@azitrainc Announces Poster Presentation at ASGCT 2026 Highlighting ATR-01 Program for Ichthyosis Vulgaris
#IchthyosisVulgaris #PrecisionDerm #Dermatology #PrecisionMedicine
https://t.co/D2aGjq0Yfv

[Azitra, Inc. @azitrainc]

More about @azitrainc - Built upon three foundational platforms for precision dermatology

#PrecisionDerm #PrecisionMedicine #SkinDisorder #RareDisease

Learn more at https://t.co/jA4P59greS

[Azitra, Inc. @azitrainc]

@azitrainc is developing a broad #pipeline of precision dermatology products

#PrecisionDerm #PrecisionMedicine #biotech $AZTR
#NethertonSyndrome
#CancerRash
#Ichthyosisvulgaris

Check it out here: https://t.co/knzrzvfxbt

[Azitra, Inc. @azitrainc]

@azitrainc - leveraging microbial & protein engineering to solve the challenges of skin diseases through 3 strategies: 1. Proprietary microbial library 2. Engineered microbes for microbial drug delivery 3. Advanced genetic engineering. https://t.co/jA4P59gZ4q #AZTR #PrecisionDerm

[Azitra, Inc. @azitrainc]

New to @azitrainc? Learn more about our appraoch - Precision dermatology powered by microbial and genetic engineering https://t.co/jA4P59gZ4q #biotech #dermatology #precisionmedicine #precisionderm #raredisease #cosmeceutical $AZTR

[Azitra, Inc. @azitrainc]

More coverage from our announcement last week -Thanks @ThePharmaLetter https://t.co/4wJRsKlegB
#biotech #dermatology #precisionmedicine #precisionderm #raredisease #cosmeceutical $AZTR

[Azitra, Inc. @azitrainc]

Thanks to @GregBordonaro at @HartfordBizl for covering our announcement last week - CT biotech raises up to $31.4M amid listing compliance push

https://t.co/UhuvplWbsp

#biotech #dermatology #precisionmedicine #precisionderm #raredisease #cosmeceutical

[Azitra, Inc. @azitrainc]

-Financing marks launch of Azitra new innovative protein and peptide research programs for the cosmetic and cosmeceutical markets

-Leverages untapped potential of Azitra's genetic engineering platform to accelerate time to commercialization

[Azitra, Inc. @azitrainc]

@azitrainc Announces Pricing of Private Placement Financing of up to Approximately $10.5 Million with up to an Additional Approximately $20.9 Million https://t.co/bpJJFwlJce

[Azitra, Inc. @azitrainc]

Highlights from our announcement yesterday:

-Initial funding of approximately $10.5MM in convertible preferred stock and up to an additional $20.9MM upon cash exercise of warrants

#biotech #dermatology #cosmeceutical $AZTR

[Azitra, Inc. @azitrainc]

How is @azitrainc's approach to precision dermatology differentiated? Designed to penetrate/delivers to skin; disease modifying; safe; low cost; and ease of use. Learn more here https://t.co/jA4P59greS